Company Focus
CVS Health
Latest CVS Health News
Pharmaceutical
US e-commerce giant Amazon has begun dispensing weight-loss drugs to eligible Medicare patients for $50 a month, plugging its pharmacy arm into a federal program that has opened the US government's largest health coverage scheme to obesity medicines for the first time. 7 August 2026
Related News
Insights
Company Spotlight
A San Carlos, California-based immunology biotech using nanobody-based multispecific biologics to target the IL-31 itch pathway, positioning its lead asset against the Dupixent franchise in atopic dermatitis and chronic pruritus.
Latest News & Features of interest to CVS Health
Pharmaceutical
German pharma and technology group Merck KGaA has upgraded its full-year outlook after a second quarter in which its laboratory and semiconductor materials businesses more than covered a weakening pharmaceutical unit. Group net sales rose 3.4% to 5.4 billion euros ($6.24 billion), equal to organic growth of 4.1%, with currency effects clipping 1.1 percentage points off the reported figure. 6 August 2026
Biotechnology
The US Food and Drug Administration (FDA) has accepted Merck & Co's supplemental Biologics License Application (sBLA) for its respiratory syncytial virus (RSV) antibody Enflonsia (clesrovimab-cfor), seeking to expand its indication to children under two years old at increased risk of severe RSV disease through their second RSV season. 6 August 2026
Biotechnology
The National Institute for Health and Care Excellence (NICE) has recommended two acalabrutinib-based combinations for National Health Service (NHS) use in England and Wales, Anglo-Swedish pharma major AstraZeneca announced. 6 August 2026
Pharmaceutical
Irish contract research organization ICON maintains its place as the most active CRO the for second quarter of 2026, and France knocks Russia from its spot with the most clinical trials initiated in Europe, according to a report by pharma intelligence platform GlobalData. 6 August 2026
Pharmaceutical
US pharma major Eli Lilly reported second-quarter 2026 revenue of $23 billion, up 48% year-on-year from $15.6 billion in the second quarter of 2025 and well ahead of Wall Street forecasts of around $20.7 billion. 6 August 2026
Biotechnology
Cambridge, USA-based mRNA vaccines company Moderna announced that the US Food and Drug Administration (FDA) has approved mFlusiva (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older. 6 August 2026
Pharmaceutical
Danish pharma major Novo Nordisk today revealed that the District Court of The Hague has granted the company a preliminary injunction against Ceban Ziekenhuisfarmacie, ordering the latter to immediately stop selling a compounded semaglutide nasal spray that infringes Novo Nordisk's intellectual property. 5 August 2026
Biotechnology
US clinical-stage biotechnology company Expedition Therapeutics, which is developing novel oral small molecule therapies for inflammatory and respiratory diseases, today announced the closing of an oversubscribed $115 million Series B financing. 5 August 2026
Pharmaceutical
More than two million women aged 40 and over in England received an National Health Service (NHS) prescription for hormone replacement therapy (HRT) in 2025/26, more than double the 800,000 recorded in 2020/21, according to new data from the NHS Business Services Authority (NHSBSA), an arm's length body of the Department of Health and Social Care. 5 August 2026
Biotechnology
US biotech Amgen reported a 10% increase in second-quarter 2026 revenue, as growth from Repatha (evolocumab), Evenity (romosozumab) and several newer medicines outweighed declining sales of products facing pricing or biosimilar pressure. 5 August 2026
Latest In Brief for CVS Health
Pharmaceutical
Codis has agreed to acquire Catalent Pharma Solutions’ Nottingham, UK, facility, expanding its contract development and manufacturing organization (CDMO) capabilities in oral solid dose development and manufacturing. The deal is expected to close in the third quarter of 2026, subject to customary conditions. 7 July 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze